On December 14, 2023, the "2nd Hengqin World Bay Area Forum Biomedical Theme Forum and 2023 21st Century Health Industry Annual Conference" was successfully held in Zhuhai. At the conference, the "2023 In Vitro Diagnostic Industry Development Report" and the results of the 2023 In Vitro Diagnostic Industry Annual Excellent Case Selection were released. Among them, Jinyu Testing won the "2023 In Vitro Diagnostic Industry Annual Excellent Case - Annual Service Star" award for its outstanding performance in the field of tumor screening and precision diagnosis.
The biomedical industry is one of the strategic emerging industries in the Greater Bay Area, and improving the level of cancer prevention and treatment is an important part of protecting the lives and health of residents. As a leading enterprise in the third-party medical examination industry in China, Jinyu Testing has always been committed to providing more affordable and high-quality testing services for tumor screening and accurate diagnosis. At this stage, with the help of independent research and development and improvement of innovation capabilities, Jinyu Testing has established a variety of cancer early screening methylation and genetic detection and diagnosis project systems, and has made use of the service network covering 90% of the country's population to sink high-quality medical resources and tumor testing services, and promote the gradual improvement of the level of screening and diagnosis in primary medical care.
This time, Jinyu Testing was able to win the "Service Star" award, reflecting the quality and professionalism of the testing services behind it, and was well received by the industry. In the field of early tumor screening, Jinyu Testing has gradually built a gene methylation detection system, which covers early screening and early diagnosis of gastric cancer, lung cancer, bladder cancer, cervical cancer and other diseases, including all cancers approved by the State Food and Drug Administration (NMPA), with an annual testing volume of nearly 200,000 cases. Thanks to this complete overall solution for early tumor screening, it has effectively contributed to the smooth development of cancer prevention and treatment in China.
In the field of clinical diagnosis and treatment, Jinyu Testing provides professional genetic testing services for the whole course of tumors, including diagnosis, medication guidance, prognosis follow-up, etc. In order to reduce the burden of patient testing, Jinyu Testing has launched the "Huimin 3000" tumor detection system, covering 17 kinds of tumors such as lung cancer, intestinal cancer, breast cancer, etc., including 86 class I and II drug genes and dozens of tumor ** monitoring-related genes, which have benefited nearly 10,000 patients.
Jinyu Testing has also carried out many public welfare activities to benefit the people, which is conducive to truly helping the implementation of the Healthy China strategy. For example, it has cooperated with Guangzhou Jinyu Public Welfare Association to carry out the public welfare activities of early tumor screening of "Stay away from cancer and guard the 'medical' line", and the public welfare activities of "Caring for Cancer, Lung Life", etc., to truly help the prevention and treatment of cancer.
Looking forward to the future, Jinyu Testing will continue to be clinically and disease-oriented, adhere to the route of benefiting the people, build a broader ecosystem, and help improve the early diagnosis rate and survival rate of cancer.
Disclaimer: The market is risky, choose carefully! This article is for reference only and is not intended as a basis for trading.